By Fineline Cube 
Gilead Sciences Inc. (NASDAQ: GILD) today announced its third‑quarter 2025 financial results. Total revenues reached $7.769 billion, a 3 % year‑over‑year (YoY) increase, while product sales declined 2 % YoY to $7.345 billion—a drop largely driven by lower Veklury (remdesivir) and cell‑therapy volumes, partially offset by higher HIV and Livdelzi (seladelpar) sales. Excluding Veklury, product sales rose 4 % YoY to approximately $7.1 billion.
Financial Highlights
| Metric | Q3 2025 | YoY % | Notes |
|---|---|---|---|
| Total Revenue | $7.769 B | +3 % | |
| Product Sales | $7.345 B | ‑2 % | |
| Product Sales (Ex‑Veklury) | $7.1 B | +4 % | |
| HIV Sales | $5.277 B | +4 % | |
| Veklury Sales | $277 M | ‑60 % |
Segment Performance
| Therapeutic Area | Sales | YoY % | Highlights |
|---|---|---|---|
| HIV | $5.277 B | +4 % | Biktarvy up 6 %; Descovy up 20 % |
| Cell Therapy | $432 M | ‑11 % | |
| Liver Disease | $819 M | +12 % | |
| Oncology (Trodelvy) | $357 M | +7 % |
Key Product Movements
- Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide) – $3.7 B, up 6 %.
- Descovy (emtricitabine + tenofovir alafenamide) – $701 M, up 20 %.
- Livdelzi (seladelpar) – growth offsetting Veklury decline.
- Veklury (remdesivir) – $277 M, down 60 % YoY.
Strategic Developments
- Patent Litigation Settlement – Gilead reached agreements with generic manufacturers that set the earliest launch of a generic Biktarvy at April 1 2036, extending exclusivity beyond the prior December 2033 projection.
- Acquisition of Interius BioTherapeutics, Inc. – The privately held CAR‑T company expands Gilead’s in‑vivo therapeutic pipeline.
Guidance Update
Based on the current quarter, Gilead has refined its full‑year 2025 product‑sales outlook to $28.4 billion – $28.7 billion, a modest upward revision from the previous $28.3 billion – $28.7 billion range.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech